Stocks · News reference
Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-endFavorable safety profile observed to date, with limited hematological
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report came out
Read original at benzingaBTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.
Read original at benzingaHC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $5 to $7.
Read original at benzinga